These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1452490)

  • 21. Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study.
    Goto H; Shimada K; Ikemoto H; Oguri T;
    J Infect Chemother; 2009 Dec; 15(6):347-60. PubMed ID: 20012724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of flurithromycin against some genital pathogens.
    Furneri PM; Tempera G; Lepore AM; Bonfanti C; Nicoletti G
    Drugs Exp Clin Res; 1991; 17(3):175-80. PubMed ID: 1914844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility.
    Niki Y; Hanaki H; Matsumoto T; Yagisawa M; Kohno S; Aoki N; Watanabe A; Sato J; Hattori R; Terada M; Koashi N; Kozuki T; Maruo A; Morita K; Ogasawara K; Takahashi Y; Watanabe J; Takeuchi K; Fujimura S; Takeda H; Ikeda H; Sato N; Niitsuma K; Saito M; Koshiba S; Kaneko M; Miki M; Nakanowatari S; Honda Y; Chiba J; Takahashi H; Utagawa M; Kondo T; Kawana A; Konosaki H; Aoki Y; Ueda H; Sugiura H; Ichioka M; Goto H; Kurai D; Okazaki M; Yoshida K; Yoshida T; Tanabe Y; Kobayashi S; Okada M; Tsukada H; Imai Y; Honma Y; Nishikawa K; Yamamoto T; Kawai A; Kashiwabara T; Takesue Y; Wada Y; Nakajima K; Miyara T; Toda H; Mitsuno N; Sugimura H; Yoshioka S; Kurokawa M; Munekawa Y; Nakajima H; Kubo S; Ohta Y; Mikasa K; Maeda K; Kasahara K; Koizumi A; Sano R; Yagi S; Takaya M; Kurokawa Y; Kusano N; Mihara E; Kuwabara M; Fujiue Y; Ishimaru T; Matsubara N; Kawasaki Y; Tokuyasu H; Masui K; Negayama K; Ueda N; Ishimaru M; Nakanishi Y; Fujita M; Honda J; Kadota J; Hiramatsu K; Aoki Y; Nagasawa Z; Suga M; Muranaka H; Yanagihara K; Fujita J; Tateyama M; Sunakawa K; Totsuka K
    J Infect Chemother; 2009 Jun; 15(3):156-67. PubMed ID: 19554400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J; Fernandes ML; Serrano N;
    Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004.
    Melo-Cristino J; Santos L; Ramirez M;
    Rev Port Pneumol; 2006; 12(1):9-30. PubMed ID: 16572254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-antibiotic effect of azithromycin on respiratory tract pathogens.
    Debbia EA; Molinari G; Paglia P; Schito GC
    Drugs Exp Clin Res; 1990; 16(12):615-9. PubMed ID: 1966617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro antibacterial activity of clarithromycin, a new macrolide antibiotic, and regression curve].
    Soussy CJ; Le Van Thoi J; Cluzel M; Derlot E; Kitzis MD
    Pathol Biol (Paris); 1990 May; 38(5):401-6. PubMed ID: 2142274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination.
    Neu HC; Chin NX; Gu JW
    J Antimicrob Chemother; 1992 Jul; 30 Suppl A():83-94. PubMed ID: 1328138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.
    Peters DH; Friedel HA; McTavish D
    Drugs; 1992 Nov; 44(5):750-99. PubMed ID: 1280567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
    Okubo T; Iyobe S; Fujiki Y; Sagai H
    Jpn J Antibiot; 2003 Jun; 56(3):163-70. PubMed ID: 12942787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Susceptibility of clinical isolates from primary care clinics to oral antibacterial agents].
    Fujimura T; Yoshida I; Yamano Y
    Jpn J Antibiot; 2007 Feb; 60(1):17-30. PubMed ID: 17436860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2011)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Apr; 68(2):105-24. PubMed ID: 26182814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG
    Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial activity and postantibiotic effect of flurithromycin against Helicobacter pylori strains.
    Fera MT; Giannone M; Pallio S; Tortora A; Blandino G; Carbone M
    Int J Antimicrob Agents; 2001 Feb; 17(2):151-4. PubMed ID: 11165121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens.
    Felmingham D; Robbins MJ; Baskerville AJ; Sanghrajka MD; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1989; 15(2):59-62. PubMed ID: 2737080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.